Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn’s Disease

Abstract Background & Aims We aim to provide guidance for medical treatment of luminal Crohn’s disease in children. Methods We performed a systematic search of publication databases to identify studies of medical management of pediatric Crohn’s disease. Quality of evidence and strength of recommendations were rated according to the GRADE (Grading of Recommendation Assessment, Development, and Evaluation) approach. We developed statements through an iterative online platform and then finalized and voted on them. Results The consensus includes 25 statements focused on medical treatment options. Consensus was not reached, and no recommendations were made, for 14 additional statements, largely due to lack of evidence. The group suggested corticosteroid therapies (including budesonide for mild to moderate disease). The group suggested exclusive enteral nutrition for induction therapy and biologic tumor necrosis factor antagonists for induction and maintenance therapy at diagnosis or at early stages of severe disease, and for patients failed by steroid and immunosuppressant induction therapies. The group recommended against the use of oral 5-aminosalicylate for induction or maintenance therapy in patients with moderate disease, and recommended against thiopurines for induction therapy, corticosteroids for maintenance therapy, and cannabis in any role. The group was unable to clearly define the role of concomitant immunosuppressants during initiation therapy with a biologic agent, although thiopurine combinations are not recommended for male patients. No consensus was reached on the role of aminosalicylates in treatment of patients with mild disease, antibiotics or vedolizumab for induction or maintenance therapy, or methotrexate for induction therapy. Patients in clinical remission who are receiving immunomodulators should be assessed for mucosal healing within 1 year of treatment initiation. Conclusions Evidence-based medical treatment of Crohn’s disease in children is recommended, with thorough ongoing assessments to define treatment success.

[1]  A. Griffiths,et al.  Phenotypic variation in paediatric IBD by age: a multi-centre prospective inception cohort study of the Canadian Children IBD Network. , 2019, Journal of Crohn's & colitis.

[2]  D. Hommes,et al.  Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial , 2017, The Lancet.

[3]  Nima Hamidi,et al.  Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies , 2017, The Lancet.

[4]  N. Narula,et al.  Enteral nutritional therapy for induction of remission in Crohn's disease. , 2018, The Cochrane database of systematic reviews.

[5]  T. Shimosegawa,et al.  Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping , 2017, Journal of Gastroenterology.

[6]  F. Carrat,et al.  Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease , 2017, JAMA.

[7]  V. Wolters,et al.  Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN , 2017, Journal of Crohn's & colitis.

[8]  Siddharth Singh,et al.  American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. , 2017, Gastroenterology.

[9]  A. Ananthakrishnan,et al.  Systematic review with meta‐analysis: enteral nutrition therapy for the induction of remission in paediatric Crohn's disease , 2017, Alimentary pharmacology & therapeutics.

[10]  A. Griffiths,et al.  Growth Improvement with Adalimumab Treatment in Children with Moderately to Severely Active Crohn's Disease , 2017, Inflammatory bowel diseases.

[11]  A. Griffiths,et al.  Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. , 2017, Gastroenterology.

[12]  R. Belanger,et al.  Cannabis and Canada's children and youth. , 2017, Paediatrics & child health.

[13]  G. Kaplan,et al.  Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis , 2017, Inflammatory bowel diseases.

[14]  A. Otley,et al.  Enteral Feeding Therapy for Maintaining Remission in Crohn’s Disease: A Systematic Review , 2017, JPEN. Journal of parenteral and enteral nutrition.

[15]  J. Kierkuś,et al.  Enteric-coated budesonide for the induction and maintenance of remission of Crohn’s disease in children , 2017, Current medical research and opinion.

[16]  D. Tanyingoh,et al.  Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases , 2017, The American Journal of Gastroenterology.

[17]  G. Gabay,et al.  Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial , 2017, Digestive Diseases and Sciences.

[18]  K. Kolho,et al.  Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease , 2017, Journal of pediatric gastroenterology and nutrition.

[19]  C. Deslandres,et al.  Prevalence and Risk Factors for Symptoms of Methotrexate Intolerance in Pediatric Inflammatory Bowel Disease , 2017, Inflammatory bowel diseases.

[20]  David Armstrong,et al.  Clinical Practice Guidelines for the Use of Video Capsule Endoscopy. , 2017, Gastroenterology.

[21]  M. Dubinsky,et al.  Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Crohn's Disease , 2017, Inflammatory bowel diseases.

[22]  P. Rutgeerts,et al.  The safety of vedolizumab for ulcerative colitis and Crohn's disease , 2016, Gut.

[23]  R. Khanna,et al.  Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease. , 2016, The Cochrane database of systematic reviews.

[24]  T. Matsui,et al.  Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial. , 2016, Journal of Crohn's & colitis.

[25]  E. Benchimol,et al.  Adrenal suppression in children treated with swallowed fluticasone and oral viscous budesonide for eosinophilic esophagitis , 2016, Allergy, Asthma & Clinical Immunology.

[26]  P. Lewindon,et al.  Early Mucosal Healing with Exclusive Enteral Nutrition is Associated with Improved Outcomes in Newly Diagnosed Children with Luminal Crohn's disease. , 2016, Journal of Crohn's & colitis.

[27]  Noor B. Dawany,et al.  Vedolizumab Therapy in Severe Pediatric Inflammatory Bowel Disease , 2016, Inflammatory bowel diseases.

[28]  A. Akobeng,et al.  Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. , 2016, The Cochrane database of systematic reviews.

[29]  D. Suskind,et al.  Ustekinumab in Pediatric Crohn Disease Patients , 2016, Journal of pediatric gastroenterology and nutrition.

[30]  M. Dubinsky,et al.  Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease , 2016, Inflammatory bowel diseases.

[31]  John T. Chang,et al.  The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium , 2016, The American Journal of Gastroenterology.

[32]  C. Parker,et al.  Anti-tuberculous therapy for maintenance of remission in Crohn's disease. , 2016, The Cochrane database of systematic reviews.

[33]  R. Hunt,et al.  The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. , 2016, Gastroenterology.

[34]  G. Bedogni,et al.  Nutrition in Pediatric Inflammatory Bowel Disease: From Etiology to Treatment. A Systematic Review , 2016, Nutrients.

[35]  A. Moss,et al.  Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease. , 2016, Journal of Crohn's & colitis.

[36]  R. Shamir,et al.  Ustekinumab for Resistant Pediatric Crohn Disease. , 2016, Journal of pediatric gastroenterology and nutrition.

[37]  R. Russell,et al.  Ustekinumab in Treatment of Refractory Paediatric Crohn Disease. , 2016, Journal of pediatric gastroenterology and nutrition.

[38]  A. Bitton,et al.  The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. , 2016, Gastroenterology.

[39]  N. Narula,et al.  Systematic review with meta‐analysis: mucosal healing is associated with improved long‐term outcomes in Crohn's disease , 2016, Alimentary pharmacology & therapeutics.

[40]  D. Amre,et al.  Steroid Administration and Growth Impairment in Children with Crohn's Disease , 2016, Inflammatory bowel diseases.

[41]  S. Varma,et al.  Sulfasalazine induced DRESS syndrome: a review of case reports. , 2016 .

[42]  H. Herfarth,et al.  Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases , 2016, Inflammatory bowel diseases.

[43]  L. A. Scherkenbach,et al.  Methotrexate for the Management of Crohn’s Disease in Children , 2016, The Annals of pharmacotherapy.

[44]  P. Rutgeerts,et al.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.

[45]  M. Rieder Is the medical use of cannabis a therapeutic option for children? , 2016, Paediatrics & child health.

[46]  D. Tanyingoh,et al.  Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[47]  Henk-Jan Guchelaar,et al.  Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. , 2015, Gastroenterology.

[48]  A. Griffiths,et al.  Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[49]  A. Paller,et al.  Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. , 2015, Journal of the American Academy of Dermatology.

[50]  T. Murdoch,et al.  Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target , 2015, The American Journal of Gastroenterology.

[51]  Frederic D Bushman,et al.  Comparative Effectiveness of Nutritional and Biological Therapy in North American Children with Active Crohn's Disease , 2015, Inflammatory bowel diseases.

[52]  K. Van Steen,et al.  Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. , 2015, Gastroenterology.

[53]  S. Bonovas,et al.  Systematic review with network meta‐analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease , 2015, Alimentary pharmacology & therapeutics.

[54]  M. Dądalski,et al.  Monotherapy With Infliximab Versus Combination Therapy in the Maintenance of Clinical Remission in Children With Moderate to Severe Crohn Disease , 2015, Journal of pediatric gastroenterology and nutrition.

[55]  A. Bitton,et al.  Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. , 2015, Gastroenterology.

[56]  P. Rutgeerts,et al.  Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease – a SONIC post hoc analysis , 2015, Alimentary pharmacology & therapeutics.

[57]  J. Rosh,et al.  Pharmacokinetics and Exposure–Efficacy Relationship of Adalimumab in Pediatric Patients with Moderate to Severe Crohn's Disease: Results from a Randomized, Multicenter, Phase-3 Study , 2015, Inflammatory bowel diseases.

[58]  L. A. Christensen,et al.  Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn’s Disease Patients Failing Infliximab , 2015, Digestive Diseases and Sciences.

[59]  Jingjing Ma,et al.  Use of antibiotics in patients with Crohn's disease: A systematic review and meta‐analysis , 2015, Journal of digestive diseases.

[60]  G. Kaplan,et al.  Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. , 2015, Gastroenterology.

[61]  M. Murad,et al.  Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis , 2014, Inflammatory bowel diseases.

[62]  E. Barnes,et al.  Are Patients with Inflammatory Bowel Disease on Chronic Immunosuppressive Therapy at Increased Risk of Cervical High-grade Dysplasia/Cancer? A Meta-analysis , 2014, Inflammatory bowel diseases.

[63]  W. Petritsch,et al.  Withdrawal of Long-Term Maintenance Treatment with Azathioprine Tends to Increase Relapse Risk in Patients with Crohn’s Disease , 2015, Digestive Diseases and Sciences.

[64]  C. Hassan,et al.  Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials , 2014, Annals of medicine.

[65]  Shuyi Li,et al.  Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy. , 2014, World journal of gastroenterology.

[66]  G. Guariso,et al.  Crohn's disease and growth deficiency in children and adolescents. , 2014, World journal of gastroenterology.

[67]  A. Griffiths,et al.  Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. , 2014, Journal of Crohn's & colitis.

[68]  J. Xu,et al.  Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. , 2014, Gastroenterology.

[69]  J. Macdonald,et al.  Methotrexate for maintenance of remission in Crohn's disease. , 2014, The Cochrane database of systematic reviews.

[70]  R. Baldassano,et al.  Routine use of thiopurines in maintaining remission in pediatric Crohn's disease. , 2014, World journal of gastroenterology.

[71]  L. Peyrin-Biroulet,et al.  Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis , 2014, Inflammatory bowel diseases.

[72]  A. Griffiths,et al.  Infliximab Maintains Durable Response and Facilitates Catch-up Growth in Luminal Pediatric Crohn's Disease , 2014, Inflammatory bowel diseases.

[73]  C. Bernstein,et al.  Canadian Association of Gastroenterology position statement regarding the use of thiopurines for the treatment of inflammatory bowel disease. , 2014, Canadian journal of gastroenterology & hepatology.

[74]  A. Jigaranu,et al.  Is Rifaximin Effective in Maintaining Remission in Crohn's Disease? , 2014, Digestive Diseases.

[75]  S. Eichner,et al.  Sa1153 Impact of Concomitant Immunosuppressant Use on Adalimumab Efficacy in Children With Moderately to Severely Active Crohn's Disease: Results From IMAgINE 1 , 2014 .

[76]  C. Calabrese,et al.  Mucosal healing in pediatric Crohn’s disease after anti-TNF therapy: a long-term experience at a single center , 2014, European journal of gastroenterology & hepatology.

[77]  R. Russell,et al.  A retrospective study showing maintenance treatment options for paediatric CD in the first year following diagnosis after induction of remission with EEN: supplemental enteral nutrition is better than nothing! , 2014, BMC Gastroenterology.

[78]  P. Rutgeerts,et al.  Adalimumab induces deep remission in patients with Crohn's disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[79]  G. Kaplan,et al.  Cannabis Use Provides Symptom Relief in Patients with Inflammatory Bowel Disease but Is Associated with Worse Disease Prognosis in Patients with Crohn's Disease , 2014, Inflammatory bowel diseases.

[80]  A. Cohen,et al.  Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. , 2014, Gastroenterology.

[81]  A. Griffiths,et al.  Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. , 2014, Gastroenterology.

[82]  Stanley B. Cohen,et al.  Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. , 2014, Gastroenterology.

[83]  J. Ariyaratnam,et al.  Association Between Thiopurine Use and Nonmelanoma Skin Cancers in Patients With Inflammatory Bowel Disease: A Meta-Analysis , 2014, The American Journal of Gastroenterology.

[84]  A. Griffiths,et al.  Hepatotoxicity Caused by Methotrexate Therapy in Children with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis , 2014, Inflammatory bowel diseases.

[85]  S. Saxena,et al.  The Role of Thiopurines in Reducing the Need for Surgical Resection in Crohn's Disease: A Systematic Review and Meta-Analysis , 2014, The American Journal of Gastroenterology.

[86]  Katherine Payne,et al.  The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[87]  Y. Falck‐Ytter,et al.  AGA American Gastroenterological Association Institute Guideline on the Use of Thiopurines , Methotrexate , and Anti – TNF-a Biologic Drugs for the Induction and Maintenance of Remission in In fl ammatory Crohn ’ s Disease , 2022 .

[88]  E. Louis,et al.  Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring , 2013, Gut.

[89]  I. Dotan,et al.  Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[90]  owski,et al.  Thiopurine S-Methyltransferase Phenotype and Genotype in Pediatric Patients with Inflammatory Bowel Disease; Implication for AzathioprineTreatment , 2013 .

[91]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[92]  L. A. Christensen,et al.  Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial , 2013, Gut.

[93]  A. Cheifetz,et al.  Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis , 2013, The American Journal of Gastroenterology.

[94]  T. Dassopoulos,et al.  American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. , 2013, Gastroenterology.

[95]  J. Macdonald,et al.  Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. , 2013, The Cochrane database of systematic reviews.

[96]  G. Greenberg,et al.  Ustekinumab induction and maintenance therapy in refractory Crohn's disease. , 2012, The New England journal of medicine.

[97]  W. Sandborn,et al.  Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry , 2012, The American Journal of Gastroenterology.

[98]  A. Griffiths,et al.  Safety and efficacy of adalimumab for moderate to severe Crohn's disease in children. , 2012, Gastroenterology.

[99]  M. Neurath,et al.  Mucosal healing in inflammatory bowel diseases: a systematic review , 2012, Gut.

[100]  P. Rutgeerts,et al.  Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. , 2012, Gastroenterology.

[101]  M. Dądalski,et al.  The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn’s disease , 2012, European journal of gastroenterology & hepatology.

[102]  P. Gionchetti,et al.  Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. , 2012, Gastroenterology.

[103]  A. Day,et al.  International survey of enteral nutrition protocols used in children with Crohn's disease , 2012, Journal of digestive diseases.

[104]  C. Edwards,et al.  The aetiology and impact of malnutrition in paediatric inflammatory bowel disease. , 2011, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

[105]  Katherine Payne,et al.  A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. , 2011, Pharmacogenomics.

[106]  E. Benchimol,et al.  Short-course Ondansetron for the Prevention of Methotrexate-induced Nausea in Children With Crohn Disease , 2011, Journal of pediatric gastroenterology and nutrition.

[107]  David C Wilson,et al.  Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification , 2011, Inflammatory bowel diseases.

[108]  P. Moayyedi,et al.  Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[109]  L. Peyrin-Biroulet,et al.  Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review , 2011, The American Journal of Gastroenterology.

[110]  P. Moayyedi,et al.  Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[111]  P. Moayyedi,et al.  Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[112]  P. Moayyedi,et al.  Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[113]  P. Moayyedi,et al.  Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis , 2011, The American Journal of Gastroenterology.

[114]  A. Griffiths,et al.  Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in children: REACH open-label extension , 2011, Current medical research and opinion.

[115]  M. Connock,et al.  A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease. , 2011, Health technology assessment.

[116]  D. Porter,et al.  A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[117]  J. Sanderson,et al.  Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease , 2010, Alimentary pharmacology & therapeutics.

[118]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[119]  P. Rutgeerts,et al.  Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. , 2010, Gastroenterology.

[120]  M. Picco Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease , 2010 .

[121]  S. Hanauer,et al.  Aminosalicylates for induction of remission or response in Crohn's disease. , 2010, The Cochrane database of systematic reviews.

[122]  S. Hutfless,et al.  Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[123]  M. Pröls,et al.  Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: A randomized placebo‐controlled trial , 2009, Inflammatory bowel diseases.

[124]  P. Rutgeerts,et al.  Oral budesonide for maintenance of remission of Crohn’s disease: a pooled safety analysis , 2009, Alimentary pharmacology & therapeutics.

[125]  J. Sarles,et al.  Efficacy of Infliximab in Pediatric Crohn's Disease: A Randomized Multicenter Open‐Label Trial Comparing Scheduled to On Demand Maintenance Therapy , 2009, Inflammatory bowel diseases.

[126]  J. Gisbert,et al.  Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review , 2009, The American Journal of Gastroenterology.

[127]  E. Benchimol,et al.  Budesonide for maintenance of remission in Crohn's disease. , 2009, The Cochrane database of systematic reviews.

[128]  M. Cepoiu,et al.  Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. , 2009, The Cochrane database of systematic reviews.

[129]  J. Sarles,et al.  Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. , 2009, Gastroenterologie clinique et biologique.

[130]  J. Macdonald,et al.  Methotrexate for maintenance of remission in Crohn's disease. , 2009, The Cochrane database of systematic reviews.

[131]  A. Cohen,et al.  Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[132]  P. Rutgeerts,et al.  A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. , 2008, Gastroenterology.

[133]  G. Guyatt,et al.  Going from evidence to recommendations , 2008, BMJ : British Medical Journal.

[134]  Gordon H Guyatt,et al.  GrADe : what is “ quality of evidence ” and why is it important to clinicians ? rATING quALITY of evIDeNCe AND STreNGTH of reCommeNDATIoNS , 2022 .

[135]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[136]  A. Griffiths,et al.  Traditional corticosteroids for induction of remission in Crohn's disease. , 2008, The Cochrane database of systematic reviews.

[137]  M. Vos,et al.  Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial , 2008, The Lancet.

[138]  P. Yenson,et al.  Azathioprine‐associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S‐methyltransferase deficiency , 2008, American journal of hematology.

[139]  A. Griffiths,et al.  Budesonide for induction of remission in Crohn's disease. , 2008, The Cochrane database of systematic reviews.

[140]  H. Szajewska,et al.  Meta‐analysis: enteral nutrition in active Crohn’s disease in children , 2007, Alimentary pharmacology & therapeutics.

[141]  A. Griffiths,et al.  Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. , 2007, Gastroenterology.

[142]  S. Uccini,et al.  Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[143]  M. Campieri,et al.  Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo‐controlled trial with rifaximin , 2006, Alimentary pharmacology & therapeutics.

[144]  M. Bala,et al.  Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease , 2006 .

[145]  J. Stein,et al.  Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study , 2006, European journal of gastroenterology & hepatology.

[146]  P. Rutgeerts,et al.  Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. , 2006, Gastrointestinal endoscopy.

[147]  Melissa S. Murphy,et al.  Treatment of active Crohn’s disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial , 2005, Gut.

[148]  P. Jacobs,et al.  Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[149]  B. Feagan,et al.  Methotrexate for induction of remission in refractory Crohn's disease. , 2005, The Cochrane database of systematic reviews.

[150]  D. Gaffney,et al.  Cost‐effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease , 2004, Alimentary pharmacology & therapeutics.

[151]  S. Bosco,et al.  Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. , 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[152]  J. Escher Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial , 2004, European journal of gastroenterology & hepatology.

[153]  A. Akobeng,et al.  Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. , 2003, The Cochrane database of systematic reviews.

[154]  A. Griffiths,et al.  Corticosteroids for maintenance of remission in Crohn's disease. , 2003, The Cochrane database of systematic reviews.

[155]  R. Baldassano,et al.  Infliximab (REMICADE) Therapy in the Treatment of Pediatric Crohn's Disease , 2003, American Journal of Gastroenterology.

[156]  R. Shamir,et al.  A Comparison of Budesonide and Prednisone for the Treatment of Active Pediatric Crohn Disease , 2003, Journal of pediatric gastroenterology and nutrition.

[157]  B. Feagan,et al.  Methotrexate for induction of remission in refractory Crohn's disease. , 2003, The Cochrane database of systematic reviews.

[158]  J. Esdaile,et al.  Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. , 2002, The Journal of rheumatology.

[159]  R. B. Canani,et al.  A semielemental diet (Pregomin) as primary therapy for inducing remission in children with active Crohn’s disease. , 2002 .

[160]  M. Langman,et al.  Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines , 2002, Gut.

[161]  C. Richart,et al.  Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial , 2002, Gut.

[162]  A. Griffiths,et al.  Controlled Ileal Release Budesonide in Pediatric Crohn Disease: Efficacy and Effect on Growth , 2001, Journal of pediatric gastroenterology and nutrition.

[163]  P. Martreau [A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators]. , 2000, Gastroenterologie clinique et biologique.

[164]  J. Markowitz,et al.  A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. , 2000, Gastroenterology.

[165]  A. Baird,et al.  Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. , 2000, Journal of pediatric gastroenterology and nutrition.

[166]  G. Greenberg,et al.  A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease , 2000 .

[167]  S. Targan,et al.  Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. , 2000, Gastroenterology.

[168]  D. Podolsky,et al.  Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. , 1999, Hepato-gastroenterology.

[169]  W. Sandborn,et al.  Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease , 1999, Clinical pharmacology and therapeutics.

[170]  A. Lavy,et al.  Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. , 1997, The American journal of gastroenterology.

[171]  D. Cook,et al.  The Relation between Systematic Reviews and Practice Guidelines , 1997, Annals of Internal Medicine.

[172]  M. Corey,et al.  Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. , 1996, Gut.

[173]  A. Messori,et al.  Defined-formula diets versus steroids in the treatment of active Crohn's disease: a meta-analysis. , 1996, Scandinavian journal of gastroenterology.

[174]  E. Cabré,et al.  How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A meta-analysis of the randomized clinical trials. , 1995, JPEN. Journal of parenteral and enteral nutrition.

[175]  A. Griffiths,et al.  Meta-analysis of enteral nutrition as a primary treatment of active Crohn's disease. , 1995, Gastroenterology.

[176]  A. Lavie,et al.  A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. , 1995, Journal of clinical gastroenterology.

[177]  Loyd,et al.  Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. , 1995, The New England journal of medicine.

[178]  M. Farthing,et al.  Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone. , 1993, Gut.

[179]  E. Cabré,et al.  Polymeric enteral diets as primary treatment of active Crohn's disease: a prospective steroid controlled trial. , 1993, Gut.

[180]  K. Lindor,et al.  A randomized prospective trial comparing a defined formula diet, corticosteroids, and a defined formula diet plus corticosteroids in active Crohn's disease. , 1992, Mayo Clinic proceedings.

[181]  A. Demetriou,et al.  Comparison of enteral nutrition and drug treatment in active Crohn's disease: results of the European Cooperative Crohn's Disease Study IV. , 1992, JPEN. Journal of parenteral and enteral nutrition.

[182]  M. Zeitz,et al.  Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's Disease Study. IV. , 1991, Gastroenterology.

[183]  K. Ewe,et al.  Feasibility and effectiveness of a defined-formula diet regimen in treating active Crohn's disease. European Cooperative Crohn's Disease Study III. , 1990, Scandinavian journal of gastroenterology.

[184]  W. Spruill,et al.  Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. , 1990, Arthritis and rheumatism.

[185]  W. Evans,et al.  Pharmacokinetics of subcutaneous methotrexate. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[186]  A. Segal,et al.  Elemental diet as primary treatment of acute Crohn's disease: a controlled trial. , 1984, British medical journal.

[187]  K. Ewe,et al.  European cooperative Crohn's disease study (ECCDS) : Results of drug treatment , 1984 .

[188]  R. Weinshilboum,et al.  Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. , 1980, American journal of human genetics.

[189]  R. Summers,et al.  National Cooperative Crohn's Disease Study: results of drug treatment. , 1979, Gastroenterology.

[190]  Norman Crolee Dalkey,et al.  An experimental study of group opinion , 1969 .